Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2001-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.45.3.857-869.2001PMID 11181372PMCID PMC90385
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

  2004cited by this paper
• Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition

  2002cited by this paper
• SCH 56592, Amphotericin B, or Itraconazole Therapy of Experimental Murine Cerebral Phaeohyphomycosis Due toRamichloridium obovoideum (“Ramichloridium mackenziei”)

  2000cited by this paper
• Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys

  2000cited by this paper
• Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis

  2000cited by this paper
• In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens

  2000cited by this paper
• High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum.

  2000cited by this paper
• Role of newer azoles in surgical patients.

  1999cited by this paper
• In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.

  1999cited by this paper
• Treatment of Murine Fusariosis with SCH 56592

  1999cited by this paper
• Comparison of a New Triazole Antifungal Agent, Schering 56592, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis in Immunocompetent Mice

  1999cited by this paper
• Five‐year‐survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long‐term survival

  1999cited by this paper
• Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

  1999cited by this paper
• Current and Emerging Azole Antifungal Agents

  1999cited by this paper
• SCH56592 treatment of murine invasive aspergillosis.

  1998cited by this paper
• Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

  1998cited by this paper
• Cytochromes P450 in fungi.

  1998cited by this paper
• In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

  1998cited by this paper
• Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

  1998cited by this paper
• Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum.

  1998cited by this paper
• Review Article Cytochromes P450 in fungi

  1998cited by this paper
• In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp

  1997cited by this paper
• Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

  1997cited by this paper
• Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

  1997cited by this paper
• The search for new triazole antifungal agents.

  1997cited by this paper
• In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts

  1997cited by this paper
• Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi

  1997cited by this paper
• Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp

  1997cited by this paper
• Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

  1997cited by this paper
• Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.

  1997cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

  1996cited by this paper
• Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.

  1996cited by this paper
• In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

  1996cited by this paper
• Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis.

  1996cited by this paper
• Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients

  1995cited by this paper
• A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis

  1995cited by this paper
• Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy

  1995cited by this paper
• Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma

  1994cited by this paper
• Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

  1994cited by this paper
• Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

  1994cited by this paper
• Epidemiology of invasive fungal infections in bone marrow transplantation. EORTC Invasive Fungal Infections Cooperative Group.

  1994cited by this paper
• Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.

  1992cited by this paper
• Nosocomial pneumonia in patients having bone marrow transplant attributable mortality and risk factors

  1992cited by this paper
• Amphotericin B. Still the 'gold standard' for antifungal therapy.

  1990cited by this paper
• Amphotericin B: 30 years of clinical experience.

  1990cited by this paper
• Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

  1988cited by this paper
• Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans

  1987cited by this paper
• Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis.

  1987cited by this paper
• Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis.

  1985cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations

  1978cited by this paper

• Cerebral diffusion of posaconazole in an experimental model of disseminated scedosporiosis.

  2025cites this paper
• Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate

  2024cites this paper
• Utilization of nanotechnology and experimental design in the development and optimization of a posaconazole‒calendula oil nanoemulgel for the treatment of mouth disorders

  2024cites this paper
• Long-Term Kinetics of Serum Galactomannan during Treatment of Complicated Invasive Pulmonary Aspergillosis

  2023cites this paper
• Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients

  2022cites this paper
• Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases

  2022cites this paper
• Diagnostic yield of a bronchoalveolar lavage fluid galactomannan assay in patients with negative serum galactomannan results suspected to have invasive pulmonary aspergillosis

  2021cites this paper
• Disposition of posaconazole after single oral administration in large falcons (Falco spp): Effect of meal and dosage and a non-compartmental model to predict effective dosage.

  2021cites this paper
• Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

  2020cites this paper
• Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?

  2020cites this paper
• The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies

  2020cites this paper
• Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy

  2020influential citation
• Pharmacokinetics and Pharmacodynamics of Posaconazole

  2020cites this paper
• Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia.

  2020cites this paper
• Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients

  2019cites this paper
• Diagnostic Approaches for Aspergillus Infections

  2019cites this paper
• Aspergillosis

  2019cites this paper
• Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis

  2018cites this paper
• Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age

  2018cites this paper
• Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.

  2017cites this paper
• Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.

  2017cites this paper
• Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis

  2017cites this paper
• Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

  2017cites this paper
• Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis

  2017cites this paper
• Laboratory diagnosis of invasive aspergillosis: review of molecular methods and detection of antigens

  2016cites this paper
• Galactomannan enzyme immunoassay and quantitative Real Time PCR as tools to evaluate the exposure and response in a rat model of aspergillosis after posaconazole prophylaxis.

  2016cites this paper
• (1→3)-β-d-Glucan and Galactomannan for Differentiating Chemical “Black Particles” and Fungal Particles Inside Peritoneal Dialysis Tubing

  2016cites this paper
• Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.

  2016cites this paper
• Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

  2016cites this paper
• Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia

  2016cites this paper
• Antifungal pharmacokinetics and pharmacodynamics.

  2015cites this paper
• B Lipid Complex and Liposomal Amphotericin B against Aspergillus

  2015cites this paper
• In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis

  2015cites this paper
• Aspergilose invasiva em pacientes imunodeprimidos: comparação entre as provas de galactomanana, 1,3 βD-glucana, dados tomográficos e desfecho clínico

  2015cites this paper
• Susceptibility of Sporothrix brasiliensis isolates to amphotericin B, azoles, and terbinafine.

  2015cites this paper
• Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis

  2015cites this paper
• Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.

  2015cites this paper
• Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus

  2015cites this paper
• Update on Posaconazole Pharmacokinetics: Comparison of Old and New Formulations

  2014cites this paper
• Galactomannan testing during mold-active prophylaxis.

  2014cites this paper
• Antifungal Pharmacokinetics and Pharmacodynamics Subject Collection Human Fungal Pathogens Pneumocystis

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

  2014cites this paper
• Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens

  2014cites this paper
• Therapeutic drug monitoring of voriconazole and posaconazole for invasive

  2013cites this paper
• Invasive fungal infections: biomarkers and molecular approaches to diagnosis.

  2013cites this paper
• The pharmacodynamics of antifungal agents against Aspergillus

  2013cites this paper
• Diagnosis of Aspergillus niger Peritonitis in a Peritoneal Dialysis Patient by Peritoneal Galactomannan and β-d-Glucan Detection

  2013cites this paper
• patients with hematological malignancies Evidence-based assessment of primary antifungal prophylaxis in

  2013cites this paper
• Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis

  2013cites this paper
• Current status of in vitro and in vivo antifungal activities of posaconazole

  2013cites this paper
• Caracterização e Identificação de Fungos Causadores de Infecções Nosocomiais em Pacientes Transplantados de Células Tronco Hematopoiéticas

  2013cites this paper
• Newer Systemic Antifungal Agents

  2012cites this paper
• Pulmonary Aspergillosis Model of Invasive In Vivo fumigatus in an Mutant Isolates of Aspergillus Cyp 51 Determination against Wild-Type and Posaconazole Pharmacodynamic Target

  2012cites this paper
• Posaconazole

  2012cites this paper
• Invasive mycoses: diagnostic challenges.

  2012cites this paper
• Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

  2012cites this paper
• Importance of Pharmacokinetic Considerations for Selecting Therapy in the Treatment of Invasive Fungal Infections

  2012cites this paper
• Posaconazole

  2012cites this paper
• The management of febrile neutropenia in the posaconazole era: a new challenge?

  2012cites this paper
• Animal Models In Mycology: What Have We Learned Over The Past 30 Years

  2012cites this paper
• Лечение грибковой инфекции у взрослых пациентов в пульмонологической практике и интенсивной терапии

  2011cites this paper
• Pharmacokinetic–pharmacodynamic optimization of triazole antifungal therapy

  2011cites this paper
• Molecular Diagnosis and Species-specific Identification of Medically Important

  2011cites this paper
• Posaconazole Plasma Concentrations in Critically Ill Patients

  2011cites this paper
• Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

  2011cites this paper
• An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

  2011cites this paper
• Role of NADPH Oxidase versus Neutrophil Proteases in Antimicrobial Host Defense

  2011cites this paper
• Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis

  2011influential citation
• Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition.

  2011cites this paper
• Molecular Detection and Species-Specific Identification of Medically Important Aspergillus Species by Real-Time PCR in Experimental Invasive Pulmonary Aspergillosis

  2011cites this paper
• Pharmacokinetic/Pharmacodynamic Profile of Posaconazole

  2010cites this paper
• Protein expression profiles distinguish between experimental invasive pulmonary aspergillosis and Pseudomonas pneumonia

  2010cites this paper
• Caracterización de los pacientes con sospecha de aspergilosis invasiva estudiados con prueba Platelia Aspergillus® Characterization of patients with suspected invasive aspergillosis studied by Platelia test

  2010cites this paper
• In Vitro Activity and In Vivo Efficacy of Posaconazole in Treatment of Murine Infections by Different Isolates of the Aspergillus terreus Complex

  2010cites this paper
• Caracterización de los pacientes con sospecha de aspergilosis invasiva estudiados con prueba Platelia Aspergillus

  2010cites this paper
• Invasive aspergillosis in pediatric patients

  2010cites this paper
• The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-d-Glucan, and Consequences of Delayed Antifungal Therapy

  2010cites this paper
• Detection of invasive aspergillosis.

  2010influential citation
• Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis

  2010cites this paper
• The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1 3 3)- (cid:1) - D -Glucan, and Consequences of Delayed Antifungal Therapy (cid:1)

  2010cites this paper
• Antifungal Therapeutic Drug Monitoring

  2010cites this paper
• The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1 3 3)- (cid:1) - D -Glucan, and Consequences of Delayed Antifungal Therapy (cid:1)

  2010cites this paper
• Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers

  2009cites this paper
• Conventional or molecular measurement of Aspergillus load.

  2009cites this paper
• Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.

  2009cites this paper
• Preemptive antifungal therapy: Do diagnostics help?

  2009cites this paper
• Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.

  2009cites this paper
• Prophylaxis for Aspergillosis

  2009cites this paper
• Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

  2009cites this paper
• Diagnostic imaging of experimental invasive pulmonary aspergillosis.

  2009cites this paper
• Use of posaconazole in the treatment of invasive fungal infections

  2009cites this paper
• Galactomannan Antigenemia in Pediatric Oncology Patients With Invasive Aspergillosis

  2008cites this paper
• In vitro activity of artemisinin in combination with clotrimazole or heat-treated amphotericin B against Plasmodium falciparum.

  2008cites this paper
• Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA)

  2008cites this paper
• Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome

  2008cites this paper
• Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

  2008cites this paper
• Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

  2008cites this paper
• Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects

  2008influential citation
• Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.

  2008cites this paper
• Therapeutic drug monitoring for triazoles

  2008cites this paper